Catalyst Pharmaceuticals (CPRX) Gross Profit (2019 - 2026)

Catalyst Pharmaceuticals has reported Gross Profit for 8 years, with the latest figure at $134.9 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 9.23% year-over-year to $134.9 million; the trailing twelve-month figure through Mar 2026 stood at $513.1 million (up 11.45% YoY), and the FY2025 full-year result was $501.7 million, up 18.64% from the prior year.
• Gross Profit for Q1 2026 stood at $134.9 million, up from $126.5 million in the prior quarter.
• The five-year high for Gross Profit was $134.9 million in Q1 2026, with the low at $37.2 million in Q1 2022.
• Historically, Gross Profit has averaged $93.3 million across 5 years, with a median of $94.8 million in 2023.
• Annual changes were most pronounced in 2023 — Gross Profit surged 102.75% — and 2025, when it grew 5.29%.
• Catalyst Pharmaceuticals' Gross Profit stood at $49.6 million in 2022, then jumped by 91.19% to $94.8 million in 2023, then gained by 26.82% to $120.2 million in 2024, then grew by 5.29% to $126.5 million in 2025, then increased by 6.62% to $134.9 million in 2026.
• The last three Gross Profit figures came in at $134.9 million (Q1 2026), $126.5 million (Q4 2025), and $125.7 million (Q3 2025), per Business Quant data.